$ACXP

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Jun 18, 2025, 1:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 19, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? — source image
Decision brief

The 30-second read

$ACXPNeutralLow
01

Why it matters

Current performance suggests sector challenges, but without recent news catalysts, the impact on individual stocks remains limited.

02

Market read

The news indicates sector-wide underperformance, which may influence investor sentiment and trading activity in related stocks.

03

What to watch

Potential upcoming clinical trial results or regulatory decisions could alter the outlook significantly.

Timing: Limited; news reflects year-to-date performance rather than immediate catalysts.

Background

The article compares year-to-date performance of Acurx Pharmaceuticals (ACXP) with BioCryst Pharmaceuticals (BCRX), highlighting sector-wide trends.

Company-level read

Ticker impact

$ACXPNeutralMedium confidence
Context

High relevance due to recent performance comparison within the sector.

Expected impact

Potential continued underperformance in the short term; long-term outlook uncertain without additional catalysts.

Evidence & confidence

Based on recent performance data and sector comparison, the trend suggests possible continued lagging, but lack of recent news or fundamental changes limits confidence.

$BCRXBullishLow confidence
Context

Moderate relevance; included due to sentiment but less impact on sector performance.

Expected impact

Limited immediate impact; potential for slight upward movement if sentiment persists.

Evidence & confidence

Sentiment is somewhat bullish, but low relevance and absence of fundamental catalysts reduce predictive confidence.

Market effects

The underperformance of ACXP may reflect broader challenges in the biotech and life sciences sectors, potentially impacting related stocks.

No significant regional effects identified.

Limited; sector-specific performance unlikely to influence global markets.

Counterpoint

The underperformance could be a temporary correction; sector-wide recovery may occur if upcoming catalysts materialize.

Key entities

  • Acurx Pharmaceuticals

    A biotech company focused on developing antibiotics.

  • BioCryst Pharmaceuticals

    A biotech firm specializing in rare disease treatments.

Related articles

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$BCRXMedAI 8/10

BioCryst (BCRX) Q2 2026 Earnings Call Transcript

BioCryst (BCRX) discussed its Q2 2026 earnings call, citing ORLADEYO revenue of $158.2M, up 10% year-on-year, and total revenue up 45% excluding the European divestiture. Paid therapy rate rose to 84% from 83% a year earlier. The company said it completed enrollment of the ALPHA-ORBIT pivotal study for navenibart, with top-line data expected in Q3 2027, and reported $113.2M non-GAAP operating profit and $350M+ cash.

$BCRXMed

BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

BioCryst Pharmaceuticals reported Q2 2026 results driven by ORLADEYO capsule demand, with total revenue up 45% YoY excluding divested European operations. Management said it ended internal drug discovery and closed its Birmingham unit. Full-year 2026 ORLADEYO guidance remains $625M to $645M. Cash and investments were over $350M.

$BCRXMed

BIOCRYST PHARMACEUTICALS INC (BCRX): Results of Operations and Financial Condition

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 mil

$VRTXMed

Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).